7 assets in Gastric Mucosa-Associated Lymphoid Tissue Lymphoma

Therapeutic assets addressing Gastric Mucosa-Associated Lymphoid Tissue Lymphoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Bismuth Subcitrate Gastric Mucosa-Associated Lymphoid Tissue Lymphoma	National Taiwan University Hospital	P2	CCC (53)
Esomeprazole Gastric Mucosa-Associated Lymphoid Tissue Lymphoma	National Taiwan University Hospital	P2	CCC (53)
Nemtabrutinib Gastric Mucosa-Associated Lymphoid Tissue Lymphoma	City of Hope Medical Center	P2	CCC (53)
Orelabrutinib Gastric Mucosa-Associated Lymphoid Tissue Lymphoma	Fudan University	P2	CCC (53)
Rituximab Gastric Mucosa-Associated Lymphoid Tissue Lymphoma	City of Hope Medical Center	P2	CCC (53)
Tetracycline Gastric Mucosa-Associated Lymphoid Tissue Lymphoma	National Taiwan University Hospital	P2	CCC (53)
Vandazole Gastric Mucosa-Associated Lymphoid Tissue Lymphoma	National Taiwan University Hospital	P2	CCC (53)